An open-label, Multinational, Phase IIIb Study to Evaluate Patient and Satisfaction, Safety and Efficacy of Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer (ML28851) in Adjuvant/Neo-Adjuvant Setting

Author
Alsalef, K.
Ozguroglu, M.
Errihani, H.
Belbaraka, R.
Goktas, B.
Cicin, I.
Oukkal, M.
Mahfouf, H.
Mezlini, A.
Larbaoui, B.
Slim, B. A.
Uslu, R.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/114761
https://doi.org/10.1016/s0959-8049(18)30535-5
Collections